Recon: FDA approves Ozempic to reduce kidney disease progression; CDC ordered to immediately halt work with WHO

• US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression (Reuters)
• The Trump administration’s latest decisions on federal health agencies, summarized and explained (STAT)
• The RFK question: Trump's HHS nominee splits biopharma before moment of truth (Endpoints)
• RFK Jr.’s step-by-step blueprint to question the safety of vaccines (STAT)
• RFK Jr. Says He’s Not Anti-Vaccine, Sees Critical Role for Shots (Bloomberg)
• CDC ordered to stop working with WHO immediately, upending expectations of an extended withdrawal (STAT)
• States say Medicaid access cut, White House says program exempt from funding freeze (Reuters)
• Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO (Reuters)

• Sarepta shares two-year DMD study data that could inform European approval decision (Endpoints)
• Trump order set to halt supply of HIV, malaria drugs to poor countries, sources say (Reuters)
• Philips to Sell Emergency Care Unit to Bridgefield Capital (Bloomberg)
• Philips CEO Warns EU Not to Block AI Innovation With Regulation (Bloomberg)
• EU Public-Private Partnership Invests €66.8M To ‘Transform Clinical Studies’ By Boosting Diversity (MedTech Insight)
• Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again (Fierce Pharma)
• Trump order set to halt supply of HIV, malaria drugs to poor countries, sources say (Reuters)

• Akero, 89bio disclose public offerings; BioAge drops Phase 2 obesity drug (Endpoints)
• Lantheus to buy radiopharma CDMO and diagnostic assets for $250M upfront (Endpoints)
• Versant's fourth obesity biotech starts with $65M and a GIP antagonist (Endpoints)
• Atalanta gets $97M boost to take two siRNAs into clinic for rare neuro disorders (Endpoints)
• ITM aims to compete with Novartis after Phase 3 radiopharma win (Endpoints)
• Cell therapy biotech Affini-T Therapeutics appears to cut staff (Endpoints)
• Top 10 most anticipated drug launches of 2025 (Fierce Pharma)
• Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June (Fierce Pharma)
• AZ, Daiichi’s Enhertu nabs 7th FDA nod, including in 'HER2-ultralow' use, in breast cancer first (Fierce Pharma)
• Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen (Fierce Pharma)
• Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz (Fierce Pharma)
• Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief (Fierce Pharma)

• FDA webpages on clinical trial diversity removed after Trump orders (MedTech Dive)
• Neko Health raises $260M to expand body scan service, fund R&D (MedTech Dive)
• Doctors expect Boston Scientific to lead PFA race, survey finds (MedTech Dive)
• RWE Meeting Pulled From Calendar As Trump Changes Continue (MedTech Insight)
• Quibim $50m Series A To Fund High-Performance Computing And US Expansion (MedTech Insight)

• Trump’s CMS freeze, and the Cole Schmidtknecht lawsuit (STAT)
• Non-profits, health groups sue over Trump's freeze on grants, loans (Reuters)
• Latest Trump memo orders freeze on federal assistance, throwing health programs into confusion (STAT)
• RFK Jr. campaign uses HHS freeze as a fundraising tool (STAT)
• Researchers reel as Trump administration moves quickly to cut funding and end DEI health programs (STAT)
• Who is protecting Americans from Marburg right now? (STAT)
• Pharmacy middlemen lose bid to toss new Hawaii complaint (Endpoints)